Dermata Therapeutics Reports Q1 2025 Financial Results with Reduced Net Loss

Dermata Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $2.3 million, a decrease from a net loss of $3.1 million in the same period of 2024. The company’s total operating expenses for the quarter were $2.34 million, down from $3.20 million year-over-year, primarily due to reduced research and development costs, which fell to $1.28 million from $1.60 million. General and administrative expenses also decreased to $1.06 million from $1.60 million, reflecting a reduction in stock-based compensation and audit fees.

The company experienced significant changes in its financial position compared to the previous fiscal period. As of March 31, 2025, Dermata's cash and cash equivalents increased to $9.72 million from $3.16 million at the end of 2024. This increase was largely attributed to successful financing activities, including a private placement in January 2025 that raised approximately $2.3 million and a subsequent inducement financing in March 2025 that generated about $5.8 million. Total liabilities rose to $2.70 million from $1.97 million, driven by higher accounts payable and accrued liabilities.

Dermata has made strategic advancements in its product development, particularly with its lead candidate, XYNGARI™, which recently completed a Phase 3 clinical trial (STAR-1) for the treatment of acne. The trial met all co-primary endpoints, demonstrating significant efficacy compared to placebo. The company plans to initiate a second Phase 3 trial (STAR-2) by the end of 2025. Additionally, Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to evaluate XYNGARI™ in combination with DAXXIFY® for treating hyperhidrosis.

Operationally, Dermata's employee headcount has increased as the company prepares for potential commercialization of its products. The company has not yet generated revenue from product sales, and it continues to rely on equity financing to fund its operations. As of March 31, 2025, Dermata had an accumulated deficit of $68 million and expects to incur further losses as it advances its clinical programs. The company anticipates that its existing cash resources will support operations into the first quarter of 2026, but it will need to raise additional capital to sustain its development efforts and operational needs.